Lawsuits for Bladder Cancer, Other Actos Probems

As a result of the manufacturer’s failure to adequately and thoroughly research the risk of bladder cancer from Actos or warn about the potential problems, compensation was pursued Actos lawsuits.

ACTOS BLADDER CANCER PROBLEMS

Actos (pioglitazone) is a medication manufactured and sold by Takeda Pharmaceuticals for treatment of Type 2 diabetes. The drug is part of the same class of medications as Avandia (rosiglitazone), which has been linked to an increased risk of heart problems. As a result of concerns about Avandia side effects, sales of Actos have grown substantially in recent years.

Contact Our Lawyers About an ACTOS INJURY LAWSUIT

Saiontz & Kirk, PA, Attorneys & Lawyers, Baltimore, MD

Studies have found that side effects of Actos may cause users to face an increased risk of bladder cancer. As a result, the potential risk of Actos cancer problems was reviewed by health regulators in the United States and other countries throughout the world years after the medication was first introduced.

Some experts believed that an Actos recall should have been issued, but much stronger warnings about the risk of bladder cancer from Actos were added to the medication in December 2016. However, many individuals may have avoided a cancer diagnosis if earlier warnings and information had been provided.

Possible signs or symptoms of Actos bladder cancer may include:

  • Blood in the Urine
  • Pain During Urination
  • Frequent Urination
  • Feeling of Need to Urinate Without Results

Although it appears that information about the risk of Actos cancer problems was known to the manufacturer for some time, inadequate warnings were provided to consumers and the medical community for years.

ACTOS CLASS ACTION LAWYERS

The attorneys at Saiontz & Kirk, P.A. are evaluating the potential for new Actos bladder cancer class action lawsuits or individual claims on behalf of individuals recently diagnosed, or who did not discover the potential cause of their injury.

Evidence suggested that the manufacturer placed their desire for profits ahead of patient safety by concealing information about the potential risk of bladder cancer. Following several years of litigation, a global Actos settlement was reached in 2015 to resolve all pending claims for about $2.4 billion.